Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial.

Masao Nakajima,Shoichi Hazama,Yukio Tokumitsu,Yoshitaro Shindo,Hiroto Matsui,Satoshi Matsukuma,Yuki Nakagami,Koji Tamada,Keiko Udaka,Michiie Sakamoto,Akira Saito, Yasunari Kouki, Toshinari Uematsu,Ming Xu,Michihisa Iida,Ryouichi Tsunedomi,Nobuaki Suzuki,Shigeru Takeda,Tatsuya Ioka,Shun Doi,Hiroaki Nagano

Hepatology research : the official journal of the Japan Society of Hepatology（2023）

引用 2|浏览8

暂无评分

摘要

This novel therapeutic vaccine was safe as perioperative immunotherapy for patients with HCC, and has the potential to strongly induce CD8 T cells infiltration into tumors.

查看译文

关键词

hLAG-3Ig plus poly-ICLC,hepatocellular carcinoma,peptide vaccination therapy,tumor immunogenicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要